Reminder: Moleculin Announces Conference Call to Discuss Recent Discovery of New Molecule and Business Update on Wednesday, February 28, 2018
HOUSTON, TX–(Marketwired – February 28, 2018) – Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced a reminder that it will host a conference call this afternoon to discuss the recent discovery of a new molecule for cancer treatment and provide a business update. The call will be at 4:30 p.m. ET on Wednesday, February 28, 2018.
Participants can dial (800) 860-2442 or (412) 858-4600 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company’s website at www.moleculin.com. A replay of the call will be available by visiting www.moleculin.com for the 90 days after the call or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10117548, through March 7, 2018.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, a modulator of hard-to-target tumor cell signaling mechanisms intended to attack tumor activity directly while also recruiting the patient’s own immune system. We are also engaged in preclinical development of additional drug candidates, including compounds targeting the metabolism of tumors.
For more information about the Company, please visit http://www.moleculin.com.
Joe Dorame, Robert Blum or Joe Diaz
Lytham Partners, LLC